Session » Systemic Sclerosis and Related Disorders – Clinical Poster II

Date: Sunday, November 13, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM: Abstract Number: 1523

Anti-RNPC3 Autoantibodies in Mixed Connective Tissue Disease Are Associated with Systemic Sclerosis Skin Involvement

1:00PM-3:00PM: Abstract Number: 1534

Blood Flow Assessment of Digital Arterioles and Capillaries in Systemic Sclerosis Patients Using Ultra-high Resolution Doppler Ultrasounds

1:00PM-3:00PM: Abstract Number: 1525

Breakthrough Infections in COVID-19 Vaccinated Patients with Systemic Sclerosis: A Survival Analysis from a Multicenter International Patient-Reported Survey

1:00PM-3:00PM: Abstract Number: 1529

Clinical Nailfold Capillaroscopy Using Dinolite Microscope in Patients with Systemic Sclerosis

1:00PM-3:00PM: Abstract Number: 1531

Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Three-Year Data from SENSCIS-ON

1:00PM-3:00PM: Abstract Number: 1540

Correlations of Soluble Interleukin-2 Receptor Serum Levels with Markers of Inflammation and Pathological High-sensitivity Troponin T and Its Possible Role as a Predictor of Early Clinical Progress in Systemic Sclerosis

1:00PM-3:00PM: Abstract Number: 1538

Decreased Prevalence of Autoimmune Connective Tissue Diseases in Type 1 and Type 2 Diabetes

1:00PM-3:00PM: Abstract Number: 1526

Developing a Screening Tool for the Detection of Interstitial Lung Disease in Systemic Sclerosis: The ILD-RISC Risk Score

1:00PM-3:00PM: Abstract Number: 1542

Exploratory Clinical Subgroup Clustering in Systemic Sclerosis – Results from the Indian Progressive Systemic Sclerosis Registry

1:00PM-3:00PM: Abstract Number: 1535

Frequency of Arrhythmias, Abnormal Electrocardiography and Sudden Cardiac Death in Systemic Sclerosis: A Systematic Review and Meta-analysis

1:00PM-3:00PM: Abstract Number: 1539

Gene Expression Meta-Analysis Reveals Aging and Cellular Senescence Signatures in Scleroderma-associated Interstitial Lung Disease

1:00PM-3:00PM: Abstract Number: 1521

Long-term Follow-Up of Participants of the Phase II Study That Evaluated Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis (ASSET Trial)

1:00PM-3:00PM: Abstract Number: 1527

Maintained Complete B Cell Depletion Is Associated with Rituximab Efficacy in Connective Tissue Disorder Interstitial Lung Disease

1:00PM-3:00PM: Abstract Number: 1541

MRI Digital Artery Volume Index (DAVIX) Predicts Future Digital Ulcers and Disease Progression in Systemic Sclerosis

1:00PM-3:00PM: Abstract Number: 1528

Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) and Organ Damage: Data from the SENSCIS Trial

1:00PM-3:00PM: Abstract Number: 1518

Prevalence, Risk Factors and Treatment Patterns of Digital Ischemic Complications in Systemic Sclerosis: A Single Center Cross-Sectional Study

1:00PM-3:00PM: Abstract Number: 1536

Progressive Interstitial Lung Disease Is Frequent Also in Late Disease Stages in Systemic Sclerosis Patients from EUSTAR

1:00PM-3:00PM: Abstract Number: 1537

Proteomic Profiling of Plasma Microvesicles Isolated from Patients with Systemic Sclerosis

1:00PM-3:00PM: Abstract Number: 1524

Risk Factors for Lung Function Decline in Systemic Sclerosis Interstitial Lung Disease in a Large Single-Center Cohort

1:00PM-3:00PM: Abstract Number: 1520

Rituximab and Tocilizumab and Their Effect on Lung Disease Progression in Scleroderma. a Retrospective Cohort Study at a Single Centre

1:00PM-3:00PM: Abstract Number: 1530

Scleroderma Renal Crisis: Time to Initiation of Therapy Does Not Affect Mortality

1:00PM-3:00PM: Abstract Number: 1522

The Collaborative National Quality and Efficacy Registry for Scleroderma: Association of Medication Use on Gastrointestinal Tract Symptoms in Early Disease

1:00PM-3:00PM: Abstract Number: 1532

The Primary Cardiomyopathy of Systemic Sclerosis on Cardiovascular Magnetic Resonance Imaging

1:00PM-3:00PM: Abstract Number: 1533

Use of Body Mass Index in Prediction of Interstitial Lung Disease Related to Systemic Sclerosis Revealed by Decision Trees

1:00PM-3:00PM: Abstract Number: 1519

Using Galacetin-3 (Gal-3) and Cardiotrophin-1 (CT-1) for Early Detection of Primary Heart Involvement in Systemic Sclerosis as Seen on Cardiac MRI

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].